Cargando…

Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury

RATIONALE & OBJECTIVE: There is limited evidence to guide follow-up after acute kidney injury (AKI). Knowledge gaps include which patients to prioritize, at what time point, and for mitigation of which outcomes. In this study, we sought to compare the net benefit of risk model–based clinical dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawhney, Simon, Tan, Zhi, Black, Corri, Marks, Angharad, Mclernon, David J., Ronksley, Paul, James, Matthew T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: W.B. Saunders 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234511/
https://www.ncbi.nlm.nih.gov/pubmed/33428996
http://dx.doi.org/10.1053/j.ajkd.2020.12.008
_version_ 1783714100652539904
author Sawhney, Simon
Tan, Zhi
Black, Corri
Marks, Angharad
Mclernon, David J.
Ronksley, Paul
James, Matthew T.
author_facet Sawhney, Simon
Tan, Zhi
Black, Corri
Marks, Angharad
Mclernon, David J.
Ronksley, Paul
James, Matthew T.
author_sort Sawhney, Simon
collection PubMed
description RATIONALE & OBJECTIVE: There is limited evidence to guide follow-up after acute kidney injury (AKI). Knowledge gaps include which patients to prioritize, at what time point, and for mitigation of which outcomes. In this study, we sought to compare the net benefit of risk model–based clinical decisions following AKI. STUDY DESIGN: External validation of 2 risk models of AKI outcomes: the Grampian -Aberdeen (United Kingdom) AKI readmissions model and the Alberta (Canada) kidney disease risk model of chronic kidney disease (CKD) glomerular (G) filtration rate categories 4 and 5 (CKD G4 and G5). Process mining to delineate existing care pathways. SETTING & PARTICIPANTS: Validation was based on data from adult hospital survivors of AKI from Grampian, 2011-2013. PREDICTORS: KDIGO-based measures of AKI severity and comorbidities specified in the original models. OUTCOMES: Death or readmission within 90 days for all hospital survivors. Progression to new CKD G4-G5 for patients surviving at least 90 days after AKI. ANALYTICAL APPROACH: Decision curve analysis to assess the “net benefit” of use of risk models to guide clinical care compared to alternative approaches (eg, prioritizing all AKI, severe AKI, or only those without kidney recovery). RESULTS: 26,575 of 105,461 hospital survivors in Grampian (mean age, 60.9 ± 19.8 [SD] years) were included for validation of the death or readmission model, and 9,382 patients (mean age, 60.9 ± 19.8 years) for the CKD G4-G5 model. Both models discriminated well (area under the curve [AUC], 0.77 and 0.86, respectively). Decision curve analysis showed greater net benefit for follow up of all AKI than only severe AKI in most cases. Both original and refitted models provided net benefit superior to any other decision strategy. In process mining of all hospital discharges, 41% of readmissions and deaths occurred among people recovering after AKI. 1,464 of 3,776 people (39%) readmitted after AKI had received no intervening monitoring. LIMITATIONS: Both original models overstated risks, indicating a need for regular updating. CONCLUSIONS: Follow up after AKI has potential net benefit for preempting readmissions, death, and subsequent CKD progression. Decisions could be improved by using risk models and by focusing on AKI across a full spectrum of severity. The current lack of monitoring among many with poor outcomes indicates possible opportunities for implementation of decision support.
format Online
Article
Text
id pubmed-8234511
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher W.B. Saunders
record_format MEDLINE/PubMed
spelling pubmed-82345112021-07-01 Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury Sawhney, Simon Tan, Zhi Black, Corri Marks, Angharad Mclernon, David J. Ronksley, Paul James, Matthew T. Am J Kidney Dis Original Investigation RATIONALE & OBJECTIVE: There is limited evidence to guide follow-up after acute kidney injury (AKI). Knowledge gaps include which patients to prioritize, at what time point, and for mitigation of which outcomes. In this study, we sought to compare the net benefit of risk model–based clinical decisions following AKI. STUDY DESIGN: External validation of 2 risk models of AKI outcomes: the Grampian -Aberdeen (United Kingdom) AKI readmissions model and the Alberta (Canada) kidney disease risk model of chronic kidney disease (CKD) glomerular (G) filtration rate categories 4 and 5 (CKD G4 and G5). Process mining to delineate existing care pathways. SETTING & PARTICIPANTS: Validation was based on data from adult hospital survivors of AKI from Grampian, 2011-2013. PREDICTORS: KDIGO-based measures of AKI severity and comorbidities specified in the original models. OUTCOMES: Death or readmission within 90 days for all hospital survivors. Progression to new CKD G4-G5 for patients surviving at least 90 days after AKI. ANALYTICAL APPROACH: Decision curve analysis to assess the “net benefit” of use of risk models to guide clinical care compared to alternative approaches (eg, prioritizing all AKI, severe AKI, or only those without kidney recovery). RESULTS: 26,575 of 105,461 hospital survivors in Grampian (mean age, 60.9 ± 19.8 [SD] years) were included for validation of the death or readmission model, and 9,382 patients (mean age, 60.9 ± 19.8 years) for the CKD G4-G5 model. Both models discriminated well (area under the curve [AUC], 0.77 and 0.86, respectively). Decision curve analysis showed greater net benefit for follow up of all AKI than only severe AKI in most cases. Both original and refitted models provided net benefit superior to any other decision strategy. In process mining of all hospital discharges, 41% of readmissions and deaths occurred among people recovering after AKI. 1,464 of 3,776 people (39%) readmitted after AKI had received no intervening monitoring. LIMITATIONS: Both original models overstated risks, indicating a need for regular updating. CONCLUSIONS: Follow up after AKI has potential net benefit for preempting readmissions, death, and subsequent CKD progression. Decisions could be improved by using risk models and by focusing on AKI across a full spectrum of severity. The current lack of monitoring among many with poor outcomes indicates possible opportunities for implementation of decision support. W.B. Saunders 2021-07 /pmc/articles/PMC8234511/ /pubmed/33428996 http://dx.doi.org/10.1053/j.ajkd.2020.12.008 Text en © 2021 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Original Investigation
Sawhney, Simon
Tan, Zhi
Black, Corri
Marks, Angharad
Mclernon, David J.
Ronksley, Paul
James, Matthew T.
Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title_full Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title_fullStr Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title_full_unstemmed Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title_short Validation of Risk Prediction Models to Inform Clinical Decisions After Acute Kidney Injury
title_sort validation of risk prediction models to inform clinical decisions after acute kidney injury
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8234511/
https://www.ncbi.nlm.nih.gov/pubmed/33428996
http://dx.doi.org/10.1053/j.ajkd.2020.12.008
work_keys_str_mv AT sawhneysimon validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT tanzhi validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT blackcorri validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT marksangharad validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT mclernondavidj validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT ronksleypaul validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury
AT jamesmatthewt validationofriskpredictionmodelstoinformclinicaldecisionsafteracutekidneyinjury